Table S2, S4, S5, S6 and S7 from Single-Cell Analysis Reveals a CD4<sup>+</sup> T-cell Cluster That Correlates with PD-1 Blockade Efficacy

Table S2, S4, S5, S6 and S7 from Single-Cell Analysis Reveals a CD4<sup>+</sup> T-cell Cluster That Correlates with PD-1 Blockade Efficacy

<p>Supplementary Table 2, 4, 5, 6, 7.</p>

সংরক্ষণ করুন:

গ্রন্থ-পঞ্জীর বিবরন
প্রধান লেখক:	Hiroshi Kagamu (14961732) (author)
অন্যান্য লেখক:	Satoshi Yamasaki (14961735) (author), Shigehisa Kitano (14961738) (author), Ou Yamaguchi (14961741) (author), Atsuto Mouri (14961744) (author), Ayako Shiono (14961747) (author), Fuyumi Nishihara (14961750) (author), Yu Miura (14961753) (author), Kosuke Hashimoto (14961756) (author), Hisao Imai (14961759) (author), Kyoichi Kaira (14961762) (author), Kunihiko Kobayashi (14961765) (author), Yae Kanai (14961768) (author), Tatsuhiro Shibata (14961771) (author), Katsuhisa Horimoto (14961774) (author)
প্রকাশিত:	2025
বিষয়গুলি:	Cancer Therapeutic Research and Development Immuno-oncology Immunotherapy Biomarkers for immunotherapy Lung Cancer Translational Research
ট্যাগগুলো:	ট্যাগ যুক্ত করুন কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!

অনুরূপ উপাদানগুলি

Table S4 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
অনুযায়ী: Stéphane Fattori (15048281)
প্রকাশিত: (2025)

File_S1 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
অনুযায়ী: Stéphane Fattori (15048281)
প্রকাশিত: (2025)

Table S1 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
অনুযায়ী: Stéphane Fattori (15048281)
প্রকাশিত: (2025)

Table S2 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
অনুযায়ী: Stéphane Fattori (15048281)
প্রকাশিত: (2025)

Table S3 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
অনুযায়ী: Stéphane Fattori (15048281)
প্রকাশিত: (2025)

Table S5 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
অনুযায়ী: Stéphane Fattori (15048281)
প্রকাশিত: (2025)

Table S6 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
অনুযায়ী: Stéphane Fattori (15048281)
প্রকাশিত: (2025)

Table S7 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
অনুযায়ী: Stéphane Fattori (15048281)
প্রকাশিত: (2025)

Table S8 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
অনুযায়ী: Stéphane Fattori (15048281)
প্রকাশিত: (2025)

Teee vs Treg Clusters DEGs DS3 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
অনুযায়ী: Ankita Mitra (17141783)
প্রকাশিত: (2025)

Figure S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
অনুযায়ী: Jian Wang (15048011)
প্রকাশিত: (2025)

Table S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
অনুযায়ী: Jian Wang (15048011)
প্রকাশিত: (2025)

Table S1 from Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8<sup>+</sup> T Cells
অনুযায়ী: Snehanshu Chowdhury (14957031)
প্রকাশিত: (2025)

CD38CD39 Population DEGs DS1 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
অনুযায়ী: Ankita Mitra (17141783)
প্রকাশিত: (2025)

Teee Gene Signature DS2 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
অনুযায়ী: Ankita Mitra (17141783)
প্রকাশিত: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
অনুযায়ী: Hansol Lee (15054787)
প্রকাশিত: (2025)

Figure S1 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
অনুযায়ী: Jian Wang (15048011)
প্রকাশিত: (2025)

Figure S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
অনুযায়ী: Jian Wang (15048011)
প্রকাশিত: (2025)

Figure S3 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
অনুযায়ী: Jian Wang (15048011)
প্রকাশিত: (2025)

Figure S5 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
অনুযায়ী: Jian Wang (15048011)
প্রকাশিত: (2025)

Figure S6 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
অনুযায়ী: Jian Wang (15048011)
প্রকাশিত: (2025)

Figure S7 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
অনুযায়ী: Jian Wang (15048011)
প্রকাশিত: (2025)

Figure S8 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
অনুযায়ী: Jian Wang (15048011)
প্রকাশিত: (2025)

Table S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
অনুযায়ী: Jian Wang (15048011)
প্রকাশিত: (2025)

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
অনুযায়ী: Hansol Lee (15054787)
প্রকাশিত: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
অনুযায়ী: Hansol Lee (15054787)
প্রকাশিত: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
অনুযায়ী: Hansol Lee (15054787)
প্রকাশিত: (2025)

Supplementary Data 1 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
অনুযায়ী: Arianna Draghi (15126339)
প্রকাশিত: (2025)

Supplementary Data 2 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
অনুযায়ী: Arianna Draghi (15126339)
প্রকাশিত: (2025)

Supplementary Data 3 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
অনুযায়ী: Arianna Draghi (15126339)
প্রকাশিত: (2025)

Supplementary Figure S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
অনুযায়ী: Alessio Cortellini (11023993)
প্রকাশিত: (2025)

Supplementary Figure S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
অনুযায়ী: Alessio Cortellini (11023993)
প্রকাশিত: (2025)

Supplementary Figure S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
অনুযায়ী: Alessio Cortellini (11023993)
প্রকাশিত: (2025)

Supplementary Figure S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
অনুযায়ী: Alessio Cortellini (11023993)
প্রকাশিত: (2025)

Supplementary Figure S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
অনুযায়ী: Alessio Cortellini (11023993)
প্রকাশিত: (2025)

Supplementary Figure S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
অনুযায়ী: Alessio Cortellini (11023993)
প্রকাশিত: (2025)

Supplementary Figure S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
অনুযায়ী: Alessio Cortellini (11023993)
প্রকাশিত: (2025)

Supplementary Figure S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
অনুযায়ী: Alessio Cortellini (11023993)
প্রকাশিত: (2025)

UMAP visualizations of extracted CD8<sup> + </sup> T and CD4<sup> + </sup> T cell barcodes, employed for downstream subsequent single-cell trajectory and classification analyses.
অনুযায়ী: Fatemeh Keikha (20917848)
প্রকাশিত: (2025)

Supplemental Figure S4 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
অনুযায়ী: Ibrahim Aldoss (15055961)
প্রকাশিত: (2025)

Cannot write session to /tmp/vufind_sessions/sess_5cu71cr02tgo80oap8shs86huu